A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
← catalyst calendarNCT05512390 · readout ≤ 193 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
154estimated
Sites
20
Countries
Australia, Canada, Israel +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-26 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
Intervention
- Drug: ABBV-319
Primary outcomes
what the primary-completion date above is the date OFNumber of Dose-Limiting Toxicities (DLT)
measured Day 42
Number of Participants with Adverse Events (AE)
measured Up to 30 Months
Maximum Observed Serum Concentration (Cmax) of ABBV-319
measured Up to 6 Months
Time to Cmax (Tmax) of ABBV-319
measured Up to 6 Months
Terminal Phase Elimination Half-Life (t1/2) of ABBV-319
measured Up to 6 Months
Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-319
measured Up to 6 Months
Antidrug Antibody (ADA)
measured Up to 6 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed